WC
HZNP

Whitney & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Whitney & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-64
Closed -$1K – 531
2018
Q3 		$1K Buy
+64
New +$1.22K ﹤0.01% 530

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Whitney & Co's HZNP Position: Q4 2018 in Review

Whitney & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2018, closing a stake of 64 shares — an estimated $1K sold.

Whitney & Co first reported a position in HZNP in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 239 funds tracked by Wall St. Rank hold HZNP as of Q4 2018.

  • Whitney & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2018 after selling out during the quarter.
  • Whitney & Co sold 64 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2018, an estimated $1K.
  • Whitney & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 1 quarter.
  • Whitney & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1K in Q3 2018.
  • 239 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.